Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.
Set Alert for Articles By Akriti Seth

Latest From Akriti Seth

AAM Urges Trump Not To Destabilize Supply Chain

The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.

United States Regulation

Henlius Has Denosumab Application Accepted In China

Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.

Biosimilars China

The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance

Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.

Manufacturing Compliance

AAM Urges Diverse Supply Chain To Mitigate Future Crises

The AAM has outlined a set of principles that it says will help protect patient access to generics and biosimilars and aid in efforts to diversify the supply chain to help mitigate future crises. The association said it would work with policymakers and other stakeholders to formulate policies to address concerns that the coronavirus pandemic has raised.

Regulation United States

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Coronavirus COVID-19 Strategy

48 US States Support Mallinckrodt Opioid Settlement

Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.

Legal Issues United States
See All
UsernamePublicRestriction

Register